Each filer's latest filing for 63909J108 since 12/18/2024, largest first.
| Filer | % of Class | Filed | ||
|---|---|---|---|---|
| Parag Mallick 13D/A | 17.6% |
3/4/2026
Event 3/2/2026
|
||
| Patel Sujal M 13D/A | 16.3% |
3/4/2026
Event 3/2/2026
|
||
| Under 5%, checked the "5 percent or less" box, or amended by a later filing (2) | ||||
|
AH Bio Fund II, L.P.
13D/A
|
4.9% |
9/11/2026
Event 9/9/2026
|
||
| AH Bio Fund II, L.P. | 4.5% | |||
| AH Equity Partners Bio II, L.L.C. | 4.5% | |||
| Andreessen Horowitz LSV Fund II, L.P. | 0.4% | |||
| AH Equity Partners LSV II, L.L.C. | 0.4% | |||
| Marc L. Andreessen | 4.9% | |||
| Benjamin A. Horowitz | 4.9% | |||
|
Perceptive Advisors LLC
13D/A
|
3.9% |
11/3/2026
Event 10/5/2026
|
||
| Perceptive Advisors LLC | 3.9% | |||
| Joseph Edelman | 3.9% | |||
| Perceptive Life Sciences Master Fund, Ltd. | 3.8% | |||
| C2 Life Sciences LLC | 0.1% | |||
| Period | Filers | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 89 | 43.0 M | $61.1M |
| 2026 Q2 | 94 | 50.2 M | $93.7M |
| 2026 Q1 | 83 | 54.3 M | $211M |
| 2025 Q4 | 68 | 58.4 M | $114M |
| 2025 Q3 | 68 | 57.9 M | $48.9M |
| 2025 Q2 | 72 | 59.8 M | $43.3M |
| 2025 Q1 | 89 | 62.8 M | $54.0M |
| 2024 Q4 | 89 | 63.9 M | $107M |
| 2024 Q3 | 84 | 64.2 M | $183M |
| 2024 Q2 | 79 | 64.0 M | $150M |
| 2024 Q1 | 74 | 63.2 M | $186M |
| 2023 Q4 | 77 | 63.4 M | $190M |
| 2023 Q3 | 77 | 45.1 M | $142M |
| 2023 Q2 | 76 | 44.8 M | $173M |
| 2023 Q1 | 75 | 44.5 M | $123M |
| 2022 Q4 | 82 | 46.1 M | $82.9M |
| 2022 Q3 | 87 | 56.4 M | $120M |
| 2022 Q2 | 84 | 57.5 M | $155M |
| 2022 Q1 | 83 | 56.0 M | $244M |
| 2021 Q4 | 83 | 59.6 M | $235M |
| 2021 Q3 | 73 | 41.0 M | $245M |
| 2021 Q2 | 59 | 39.0 M | $380M |